ESC 365 - Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial

Open Access

Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial

Session: Clinical trials updates in medical therapy

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor S. Chatur (Boston, US)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Safia Chatur

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

1 presentation

0 follower

6 more presentations in this session

Discussant panel

Effects of finerenone on readmissions for heart failure: a prespecified secondary analysis of the FINEARTS-HF trial

Speaker: Doctor A. Bhatt (San Francisco, US)

Intravenous ferric carboxymaltose in heart failure with iron deficiency

Speaker: Doctor M. Karakas (Hamburg, DE)

Efficacy of intravenous iron for the treatment of heart failure varies by method of meta-analysis: a Bayesian and frequentist reappraisal of the evidence

Speaker: Doctor A. Henderson (Glasgow, GB)

The effect of omecamtiv mecarbil on outcomes analysed using the win ratio: an exploratory analysis of GALACTIC-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Access the full session

Clinical trials updates in medical therapy

Speakers: Doctor S. Chatur, Doctor A. Bhatt, Doctor M. Karakas, Doctor A. Henderson, Doctor K. Docherty

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources